We are live on ! Find out more
CAPR icon

Capricor Therapeutics
CAPR

22 hedge funds and large institutions have $3.34M invested in Capricor Therapeutics in 2016 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

15% more capital invested

Capital invested by funds: $2.9M → $3.34M (+$433K)

0% more funds holding

Funds holding: 22 → 22 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

Holders
22
Holders Change
–
Holders Change %
0%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
5
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$659K
2
GPCM
Granite Point Capital Management
Massachusetts
+$254K
3
FWM
Frontier Wealth Management
Missouri
+$177K
4
Citadel Advisors
Citadel Advisors
Florida
+$106K
5
CBA
Coastal Bridge Advisors
Connecticut
+$18.8K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$73K
2
VKH
Virtu KCG Holdings
New York
-$60K
3
Goldman Sachs
Goldman Sachs
New York
-$17.9K
4
UBS Group
UBS Group
Switzerland
-$12K
5
GC
Globeflex Capital
California
-$1K

CAPR Hedge Fund Activity: Q3 2016 in Review

22 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Capricor Therapeutics (CAPR) for Q3 2016, worth a combined $3.34M — up 15% from $2.9M a quarter earlier.

Fund positioning in CAPR was balanced in Q3 2016: 4 funds opened new positions, 4 closed out, 5 added to existing stakes and 3 trimmed.

The largest buyer was Sabby Management, adding an estimated $659K. The largest seller was Millennium Management, exiting entirely with an estimated $73K sold.

  • 22 institutional investors held Capricor Therapeutics (CAPR) as of Q3 2016, unchanged from Q2 2016.
  • Funds reported $3.34M of Capricor Therapeutics stock for Q3 2016, up 15% quarter-over-quarter.
  • 4 funds opened new Capricor Therapeutics positions in Q3 2016 and 4 closed out, a net change of 0 holders.
  • The largest Capricor Therapeutics buyer in Q3 2016 was Sabby Management, an estimated $659K added.
  • The largest Capricor Therapeutics seller in Q3 2016 was Millennium Management, an estimated $73K sold.

Based on aggregated 13F filings for Q3 2016.